RecallRadar

FDA Drug recall D-1207-2019

Absorica (Isotretinoin) Capsules 30 mg USP, 30 capsules (3x10 Prescription Packs) Rx only, Manufactured by: Galephar Pharmaceutical Researc…

On 2018-12-26 the FDA classified a Class III recall of Absorica (Isotretinoin) Capsules 30 mg USP, 30 capsules (3x10 Prescription Packs) Rx only, Manufactured by: Galephar Pharmaceutical Researc… by Sun Pharmaceutical Industries, citing subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1207-2019
ClassificationClass III
Statusterminated
Initiated2018-12-07
Published2018-12-26
Last updated2026-09-13 11:52 UTC
CompanySun Pharmaceutical Industries
DistributionUS

Product

Absorica (Isotretinoin) Capsules 30 mg USP, 30 capsules (3x10 Prescription Packs) Rx only, Manufactured by: Galephar Pharmaceutical Research Inc. Humacao, PR 00792, Distributed by: Sun Pharmaceutical Industries Inc. Cranbury, NJ 08512, UPC 310631117313, NDC 10631-117-31 (carton) NDC10631-117-69 (prescription pack)

Reason

Subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.

Identifiers

upc310631117313
ndc10631-115-69
ndc10631-115-31
ndc10631-116-69
ndc10631-116-31
ndc10631-117-69
ndc10631-117-31
ndc10631-118-69
ndc10631-118-31
ndc10631-133-69
ndc10631-133-31
ndc10631-134-69
ndc10631-134-31
ndc10631-002-31
ndc10631-003-31
ndc10631-004-31
ndc10631-005-31
ndc10631-006-31
ndc10631-007-31
ndc3106311173
code_infoLot: 17F28AA, Exp 1/2020

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1207-2019%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.